Breast CancerONKODETOXNCT03371732
Effectiveness of Screening and Brief Interventions for Alcohol and Tobacco During Breast Cancer Treatment (ONKODETOX)
A study testing Motivational Intervention group and Educational advises group in people with Breast Cancer and Psychology, Social, run by Institut Bergonié at 1 site in France.
Trial summary
Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings. Motivational brief interventions are recognized as particularly effective in changing health behaviors, especially consumption behaviors. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Psychology, Social
- What is being tested?
- Motivational Intervention group and Educational advises group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2016to Apr 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- women with primary breast cancer, without ongoing support for substance use.
- An AUDIT-C score >1 or more than one cigarette smoked per day.
- Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index >70).
Who cannot join
- Patients who currently use substances for which a second-line care is already committed.
- Patients with a Karnofsky index <70.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of Screening and Brief Interventions for Alcohol and/or Tobacco During Breast Cancer Treatment: A Phase III, Pilot Prospective Randomized Trial (ONKODETOX)
Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings. Motivational brief interventions are recognized as particularly effective in changing health behaviors, especially consumption behaviors. The motivational approach is more and more used in primary care setting but still few studies explore its effectiveness with breast cancer patients.
This study aims to compare two intervention arms : educational advices intervention (EAI) versus brief motivational intervention (BMI) for alcohol and/or tobacco consumption in breast cancer women, during their treatment.
In this pilot prospective randomized trial, various psychological and behavioral, variables are measured (alcohol and tobacco consumption, distress, anxiety and depressive disorders, quality of life, motivation for change, empowerment) before the brief intervention, and after 3 and 6 month.
Read the detailed description
Context :
It is now well documented that alcohol and tobacco reduce the effectiveness of a treatment, increase the side effects, favor the recurrence and/or secondary cancers and affects the quality of life of patients treated for cancer, including breast cancer. The announcement of the disease could create a window of opportunity for change in lifestyle for patients. The 2014-2019 French Cancer Plan emphasizes the need for the implementation of prevention and risk reduction related to alcohol and tobacco. A screening, brief motivational and referral to treatment program, specifically dedicated to oncology can be public health approach aiming to reduce the harmful consequences of substance misuse and improving the prognosis and quality of life of consumers at risk.
Main objective :
Evaluate effectiveness of a brief motivational intervention for alcohol and/or tobacco in short (3 month) and medium (6 month) terms in breast cancer patients, in a prospective randomized pilot study.
Secondary objectives :
- Determine the behavioral and psychopathological specific characteristics of the patient linked to change process and maintain.
- Define a brief intervention for alcohol/tobacco consumption model adapted and integrated to patient treated for cancer according to psychosocial factors highlighted.
The investigators will seek to highlight the benefit of a motivational brief intervention versus standardized educational advice. The specificity of these interventions is to be integrated in an interview integrating a systematic screening of the emotional distress of the patient, of these concerns as well as of his perceived need for aids.
Method :
This is a randomized clinical trial comparing two interventions. The trial includes 200 primary breast cancer patients with a positive AUDIT-C score and/or are tobacco consumers, randomly placed in two groups :
G1 : Motivational Intervention group (N = 100) : Participants in the intervention group benefit a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
G2 : Educational advises group (N = 100) : Participants in this group benefit of brief educational advises (10 minutes interview maximum), and received a pamphlet on the health effects of alcohol and tobacco consumption. For obvious ethical reasons, the investigators selected an intervention in the form of advice concerning the effects of the product and the submission of specific documentation (criteria not retained in the context of the brief intervention model). It did not seem possible to evaluate patients without offering them the possibility of a low threshold intervention.
Detailed scripts for each modality of intervention are realized.
Measurement :
Three sets of measurements are taken at baseline, 3-month and 6 month follow-up.
Primary Outcome measures: Clinically significant reduction (beneficial to health) of risk behaviours (alcohol and/or tobacco consumption) :
- Concerning subjects with only alcohol consumption at baseline : The intervention will be considered effective at 3 months if an individual decrease of 20% in the AUDIT score is observed at 3 months compared to the value collected at baseline; The intervention will be considered effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline.
- The same applies to subjects with only tobacco consumption at baseline: The intervention will be considered effective at 3 months if an individual decrease of 20% in the number of cigarettes consumed per day is observed at 3 months compared to the value collected at baseline; The intervention will be judged effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline.
- Finally, with regard to women with both alcohol and tobacco use at baseline :
The intervention will be considered effective if at least one of the two scores (AUDIT or number of cigarettes consumed per day) has decreased by 20% at 3 months (maintained at 6 months) compared to the value collected at baseline, with no increase in the other score.
Secondary outcome measures :
- Individual reduction of around 20% in average daily consumption of alcohol and/or tobacco (calculated on the basis of patients' consumption schedules) between inclusion and the first follow-up at 3 months, and maintenance of this success at the second follow-up at 6 months (with no increase in other consumption if the subject has both alcohol and tobacco consumption at inclusion);
- Description of the variables relating to the consumption of alcohol, tobacco, the current medico-psychological situation, psychological distress, anxio-depressive symptomatology, willingness to change alcohol and/or tobacco consumption habits;
- Improved quality of life in the experimental intervention arm compared to the standard intervention arm
Study procedure :
SCREENING-PRE-INCLUSION: Screening of distress and alcohol/tobacco consumptions is realized when the patients arrive in the oncology department for their chemotherapy treatment, by a research assistant-psychologist. Researchers propose to eligible patients to participate to the study. This first contact permits to check the absence of non-inclusion criteria; to ensure the informed consent of the person (an information and consent note will be given to him) and according to these elements, to define the provisional timetable for participation in the research.
T0 - INCLUSION AND RANDOMIZATION The research assistant retrieves the signed consent, ensuring a time available to return if necessary and carries out the research interview/assessment. The randomization is realized following this interview.
INTERVENTION: Brief intervention (G1 : Brief motivational intervention or G2 : educational advices) are conducted by the research assistant-psychologist, at the Institut Bergonié or by telephone if needed.
T1: MONITORING - FOLLOW-UP(3 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary.
T2: MONITORING - FOLLOW-UP (6 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary.
Randomization procedure :
The randomization procedure is done via the TENALEA server, managed by the Epidemiological and Clinical Research Unit (UREC) of the Bergonié Institute.
Expected results :
Highlighting:
- The efficacy of motivational brief intervention on alcohol and tobacco consumption in patients treated for breast cancer ; versus educational advices intervention.
- Psychosocial risk factors involved in maintaining problematic consumption or in the rapid relapse of tobacco/alcohol consumption.
- Conditions
- Breast Cancer, Psychology, Social
- Being tested
- Motivational Intervention group, Educational advises group
- Keywords
- Psychological intervention Alcohol, Tobacco consumption, Substance use, Health risk behavior, Oncology setting, Women, Supportive care
- Medical subject headings
- Breast Neoplasms, Tobacco Use, Substance-Related Disorders, Health Risk Behaviors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Motivational Intervention groupBehavioural
Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
Educational advises groupBehavioural
Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
| Study group | Role | What they receive |
|---|---|---|
| Groupe 1 | Other | G1 : Motivational Intervention group Receives: Behavioral: Motivational Intervention group |
| Groupe 2 | Other | G2 : Educational advises group Receives: Behavioral: Educational advises group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months
Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months
AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Measured: 3 months
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months
Individual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months.
Success depends on tobacco consumption at 3 months and 6 months.
AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Measured: 3 months and 6 months
Secondary outcomes (23)
Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption
Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion).
Measured: 3 months
Number of Patients With Decreased Alcohol and/or Tobacco Consumption
Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months and a continuation of this reduction at the second follow-up at 6 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion).
Success depends on alcohol and tobacco level consumption at 3 months and 6 months.
Measured: 3 months and 6 months
Number of Patients Per Current Treatments at Baseline
Measured: Baseline
Number of Patients Per Current Treatments at 3 Months
Measured: 3 months
Number of Patients Per Current Treatments at 6 Months
Measured: 6 months
Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months
Ongoing psychotropic treatment(s) at baseline, 3 months and 6 months.
Measured: Baseline, 3 months and 6 months
Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State
Current monitoring with regard to behaviour/emotional state
Measured: Baseline, 3 months and 6 months
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline
Type of professional followed for behaviour/emotional state at baseline
Measured: Baseline
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months
Type of professional followed for behaviour/emotional state at 3 months
Measured: 3 months
Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months
Type of professional followed for behaviour/emotional state at 6 months
Measured: 6 months
AUDIT Score at Baseline, 3 Months, and 6 Months
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 (No alcohol consumption) to 12 (alcohol dependence). Consumption profiles can be derived from this.
Higher scores indicate a worse outcome: alcohol dependence.
Measured: Baseline, 3 months, 6 months
Currently, How Many Cigarettes Per Day do You Smoke on Average?
Measured: Baseline, 3 months and 6 months
Number of Patients Who Consume Electronic Cigarettes
Measured: Baseline, 3 months and 6 months
Type of Consumption of Electronic Cigarettes
Measured: Baseline, 3 months and 6 months
Fagerström Score
Fagerström test assesses tobacco consumption and makes it possible to describe patterns of tobacco addiction. Its score ranges from 0 (non-addiction to smoking) to 10 (strong or very strong dependence on tobacco).
Measured: Baseline, 3 months, 6 months
MADRS Score
MADRS (Montgomery-Åsberg Depression Rating Scale) assesses the severity of depression in patients with mood disorders. Its score ranges from 0 (normothymic) to 60 (depression).
Measured: Baseline, 3 months, 6 months
Score of Hamilton
Hamilton test assesses symptoms of anxiety. Its score ranges from 0 to 56. The higher the score is, the more severe the depression is.
Measured: Baseline, 3 months and 6 months
Standardised Quality of Life Scores (EORTC - QLQ-C30)
QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions :
- 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning;
- 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties;
- 1 global health dimension: Global health status/QoL
Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
Measured: 3 months
Standardised Quality of Life Scores (EORTC - QLQ-C30)
QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions :
- 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning;
- 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties;
- 1 global health dimension: Global health status/QoL
Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
Measured: 6 months
HEIQ Score
HEIQ (Health Education Impact Questionnaire) assesses the concept of empowerment (health-promoting behaviours, commitment, social integration, etc.). Its scores range from 0 to 160. Higher scores mean a better health-related empowerment .
Measured: Baseline, 3 months, 6 months
Motivation Score to Change Consumption Habits (Alcohol/Tobacco)
This score ranges from 0 to 140.
The questionnaire consists of 14 questions on motivation to change alcohol/tobacco consumption habits, each with a response scale ranging from 0 (probably not) to 10 (probably).
For each question, a sub-score ranges from 0 to 10 is given and then a total score of motivation to change consumption habits is calculated by adding up all the answers to the 14 items.
The higher the score is, greater the patient's willingness to change his or her alcohol/tobacco consumption.
Measured: Baseline, 3 months and 6 months
Satisfaction Questionnaire
Measured: 3 months
On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?
Satisfaction score ranges from 1 to 10. Low scores indicate less satisfaction.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2017
- Study startMar 2016
- Primary completionNov 2018
- Study completionApr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 104 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institut Bergonié
- Sponsor type
- University, hospital or other
- Collaborators
- Ligue contre le cancer, France
- Responsible party
- Sponsor
- Investigators
- Marion BARRAULT-COUCHOURON, PhD, Principal investigator, Institut Bergonié
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03371732
- Sponsor's protocol ID
- IB2013-ONKODETOX
- Acronym
- ONKODETOX
- Status last verified
- Dec 2022
- First submitted
- 9 Nov 2017
- Last updated
- 2 Dec 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Screening and Brief Interventions for Alcohol and/or Tobacco During Breast Cancer Treatment: A Phase III, Pilot Prospective Randomized Trial (ONKODETOX)
- ClinicalTrials.gov ID
- NCT03371732
- Acronym / sponsor ID
- ONKODETOX / IB2013-ONKODETOX
- Conditions
- Breast Cancer, Psychology, Social
- Keywords
- Psychological intervention Alcohol, Tobacco consumption, Substance use, Health risk behavior, Oncology setting, Women, Supportive care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 104 participants (actual)
- Lead sponsor
- Institut BergoniéUniversity, hospital or other
- Collaborators
- Ligue contre le cancer, France
- Study start
- Mar 2016 (actual)
- Primary completion
- Nov 2018 (actual)
- Study completion
- Apr 2019 (actual)
- First posted
- 13 Dec 2017 (actual)
- Results
- Posted 3 May 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings. Motivational brief interventions are recognized as particularly effective in changing health behaviors, especially consumption behaviors. The motivational approach is more and more used in primary care setting but still few studies explore its effectiveness with breast cancer patients.
This study aims to compare two intervention arms : educational advices intervention (EAI) versus brief motivational intervention (BMI) for alcohol and/or tobacco consumption in breast cancer women, during their treatment.
In this pilot prospective randomized trial, various psychological and behavioral, variables are measured (alcohol and tobacco consumption, distress, anxiety and depressive disorders, quality of life, motivation for change, empowerment) before the brief intervention, and after 3 and 6 month.
Detailed description
Context :
It is now well documented that alcohol and tobacco reduce the effectiveness of a treatment, increase the side effects, favor the recurrence and/or secondary cancers and affects the quality of life of patients treated for cancer, including breast cancer. The announcement of the disease could create a window of opportunity for change in lifestyle for patients. The 2014-2019 French Cancer Plan emphasizes the need for the implementation of prevention and risk reduction related to alcohol and tobacco. A screening, brief motivational and referral to treatment program, specifically dedicated to oncology can be public health approach aiming to reduce the harmful consequences of substance misuse and improving the prognosis and quality of life of consumers at risk.
Main objective :
Evaluate effectiveness of a brief motivational intervention for alcohol and/or tobacco in short (3 month) and medium (6 month) terms in breast cancer patients, in a prospective randomized pilot study.
Secondary objectives :
- Determine the behavioral and psychopathological specific characteristics of the patient linked to change process and maintain.
- Define a brief intervention for alcohol/tobacco consumption model adapted and integrated to patient treated for cancer according to psychosocial factors highlighted.
The investigators will seek to highlight the benefit of a motivational brief intervention versus standardized educational advice. The specificity of these interventions is to be integrated in an interview integrating a systematic screening of the emotional distress of the patient, of these concerns as well as of his perceived need for aids.
Method :
This is a randomized clinical trial comparing two interventions. The trial includes 200 primary breast cancer patients with a positive AUDIT-C score and/or are tobacco consumers, randomly placed in two groups :
G1 : Motivational Intervention group (N = 100) : Participants in the intervention group benefit a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
G2 : Educational advises group (N = 100) : Participants in this group benefit of brief educational advises (10 minutes interview maximum), and received a pamphlet on the health effects of alcohol and tobacco consumption. For obvious ethical reasons, the investigators selected an intervention in the form of advice concerning the effects of the product and the submission of specific documentation (criteria not retained in the context of the brief intervention model). It did not seem possible to evaluate patients without offering them the possibility of a low threshold intervention.
Detailed scripts for each modality of intervention are realized.
Measurement :
Three sets of measurements are taken at baseline, 3-month and 6 month follow-up.
Primary Outcome measures: Clinically significant reduction (beneficial to health) of risk behaviours (alcohol and/or tobacco consumption) :
- Concerning subjects with only alcohol consumption at baseline : The intervention will be considered effective at 3 months if an individual decrease of 20% in the AUDIT score is observed at 3 months compared to the value collected at baseline; The intervention will be considered effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline.
- The same applies to subjects with only tobacco consumption at baseline: The intervention will be considered effective at 3 months if an individual decrease of 20% in the number of cigarettes consumed per day is observed at 3 months compared to the value collected at baseline; The intervention will be judged effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline.
- Finally, with regard to women with both alcohol and tobacco use at baseline :
The intervention will be considered effective if at least one of the two scores (AUDIT or number of cigarettes consumed per day) has decreased by 20% at 3 months (maintained at 6 months) compared to the value collected at baseline, with no increase in the other score.
Secondary outcome measures :
- Individual reduction of around 20% in average daily consumption of alcohol and/or tobacco (calculated on the basis of patients' consumption schedules) between inclusion and the first follow-up at 3 months, and maintenance of this success at the second follow-up at 6 months (with no increase in other consumption if the subject has both alcohol and tobacco consumption at inclusion);
- Description of the variables relating to the consumption of alcohol, tobacco, the current medico-psychological situation, psychological distress, anxio-depressive symptomatology, willingness to change alcohol and/or tobacco consumption habits;
- Improved quality of life in the experimental intervention arm compared to the standard intervention arm
Study procedure :
SCREENING-PRE-INCLUSION: Screening of distress and alcohol/tobacco consumptions is realized when the patients arrive in the oncology department for their chemotherapy treatment, by a research assistant-psychologist. Researchers propose to eligible patients to participate to the study. This first contact permits to check the absence of non-inclusion criteria; to ensure the informed consent of the person (an information and consent note will be given to him) and according to these elements, to define the provisional timetable for participation in the research.
T0 - INCLUSION AND RANDOMIZATION The research assistant retrieves the signed consent, ensuring a time available to return if necessary and carries out the research interview/assessment. The randomization is realized following this interview.
INTERVENTION: Brief intervention (G1 : Brief motivational intervention or G2 : educational advices) are conducted by the research assistant-psychologist, at the Institut Bergonié or by telephone if needed.
T1: MONITORING - FOLLOW-UP(3 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary.
T2: MONITORING - FOLLOW-UP (6 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary.
Randomization procedure :
The randomization procedure is done via the TENALEA server, managed by the Epidemiological and Clinical Research Unit (UREC) of the Bergonié Institute.
Expected results :
Highlighting:
- The efficacy of motivational brief intervention on alcohol and tobacco consumption in patients treated for breast cancer ; versus educational advices intervention.
- Psychosocial risk factors involved in maintaining problematic consumption or in the rapid relapse of tobacco/alcohol consumption.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Groupe 1 | Other | Behavioral: Motivational Intervention groupG1 : Motivational Intervention group |
| Groupe 2 | Other | Behavioral: Educational advises groupG2 : Educational advises group |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- women with primary breast cancer, without ongoing support for substance use.
- An AUDIT-C score >1 or more than one cigarette smoked per day.
- Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index >70).
Key exclusion criteria (2 listed)
- Patients who currently use substances for which a second-line care is already committed.
- Patients with a Karnofsky index <70.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Motivational Intervention groupParticipants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention. | Behavioural | Groupe 1 |
| Educational advises groupParticipants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption. | Behavioural | Groupe 2 |
Primary outcome
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months
Time frame: 3 months
Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months
Time frame: 3 months and 6 months
Individual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months. Success depends on tobacco consumption at 3 months and 6 months. AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
23 secondary outcomes
Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption
Time frame: 3 months
Number of Patients With Decreased Alcohol and/or Tobacco Consumption
Time frame: 3 months and 6 months
Number of Patients Per Current Treatments at Baseline
Time frame: Baseline
Number of Patients Per Current Treatments at 3 Months
Time frame: 3 months
Number of Patients Per Current Treatments at 6 Months
Time frame: 6 months
Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months
Time frame: Baseline, 3 months and 6 months
Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State
Time frame: Baseline, 3 months and 6 months
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline
Time frame: Baseline
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months
Time frame: 3 months
Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months
Time frame: 6 months
AUDIT Score at Baseline, 3 Months, and 6 Months
Time frame: Baseline, 3 months, 6 months
Currently, How Many Cigarettes Per Day do You Smoke on Average?
Time frame: Baseline, 3 months and 6 months
Number of Patients Who Consume Electronic Cigarettes
Time frame: Baseline, 3 months and 6 months
Type of Consumption of Electronic Cigarettes
Time frame: Baseline, 3 months and 6 months
Fagerström Score
Time frame: Baseline, 3 months, 6 months
MADRS Score
Time frame: Baseline, 3 months, 6 months
Score of Hamilton
Time frame: Baseline, 3 months and 6 months
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Time frame: 3 months
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Time frame: 6 months
HEIQ Score
Time frame: Baseline, 3 months, 6 months
Motivation Score to Change Consumption Habits (Alcohol/Tobacco)
Time frame: Baseline, 3 months and 6 months
Satisfaction Questionnaire
Time frame: 3 months
On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?
Time frame: 3 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Undecided
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marion BARRAULT-COUCHOURON, PhD principal investigator
Institut Bergonié
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Motivational Intervention group and Educational advises group in people with Breast Cancer and Psychology, Social, run by Institut Bergonié at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2022.